BioXcel Therapeutics implements 1-for-16 reverse stock split to meet Nasdaq listing requirement.

From GlobeNewswire: 2025-02-06 07:00:00

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is implementing a 1-for-16 reverse stock split of its common stock effective on February 7, 2025, to address the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Following the split, the company’s common stock will trade under the symbol “BTAI” with new CUSIP number 09075P204. Fractional shares will not be issued, and adjustments will be made to stock options and equity incentive plans. The reverse stock split was approved by stockholders and will automatically convert every 16 shares into one share of common stock. Contact BioXcel Therapeutics for more information.



Read more at GlobeNewswire: BioXcel Therapeutics Announces Reverse Stock Split